NASDAQ · Financial Statements
Kronos Bio, Inc. (KRON) Financial Statements
$0.88
NASDAQ: KRON
Market Cap $53.65M
Overview Financials Dividend
Kronos Bio, Inc. most recently reported annual revenue of $10.0M, a net loss of $86.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2020 2021 2022 2023 2024
Revenue $0 $0 $0 $6.0M $10.0M Operating Profit $-58.0M $-151.0M $-137.0M $-122.0M $-93.0M Net Profit $-64.0M $-149.0M $-129.0M $-113.0M $-86.0M EPS $-1.19 $-2.72 $-2.30 $-1.95 $-1.43 Op Margin — — — -1937.5% -943.2%
Balance Sheet (USD)
Metric 2020 2021 2022 2023 2024
Total Assets $512.0M $391.0M $295.0M $213.0M $124.0M Total Liabilities $46.0M $46.0M $50.0M $54.0M $37.0M Cash $462.0M $340.0M $76.0M $64.0M $85.0M Borrowings $32.0M $34.0M $31.0M $28.0M $25.0M
Cash Flow (USD)
Metric 2020 2021 2022 2023 2024
Operating Cash Flow $-38.0M $-118.0M $-91.0M $-79.0M $-65.0M Investing Cash Flow $-170.0M $59.0M $-33.0M $66.0M $85.0M Financing Cash Flow $264.0M $6.0M $1.0M $1.0M $0 Net Cash Flow $217.0M $-50.0M $-122.0M $-12.0M $20.0M Free Cash Flow $-47.0M $-122.0M $-92.0M $-79.0M $-65.0M
Valuation & Return Ratios
Metric Value PEG Ratio -0.01 EV / EBITDA 0.10 FCF Yield -121.97% Quick Ratio 7.54 Interest Coverage — Return 1Y — Return 3Y — Return 5Y —
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .